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Parkin is a unique, multifunctional ubiquitin ligase whose various roles in the cell,
particularly in neurons, are widely thought to be protective. The pivotal role that Parkin
plays in maintaining neuronal survival is underscored by our current recognition that
Parkin dysfunction represents not only a predominant cause of familial parkinsonism
but also a formal risk factor for the more common, sporadic form of Parkinson’s
disease (PD). Accordingly, keen research on Parkin over the past decade has led to
an explosion of knowledge regarding its physiological roles and its relevance to PD.
However, our understanding of Parkin is far from being complete. Indeed, surprises
emerge from time to time that compel us to constantly update the paradigm of
Parkin function. For example, we now know that Parkin’s function is not confined to
mere housekeeping protein quality control (QC) roles but also includes mitochondrial
homeostasis and stress-related signaling. Furthermore, emerging evidence also suggest
a role for Parkin in several other major neurodegenerative diseases including Alzheimer’s
disease (AD) and Amyotrophic Lateral Sclerosis (ALS). Yet, it remains truly amazing
to note that a single enzyme could serve such multitude of functions and cellular
roles. Clearly, its activity has to be tightly regulated. In this review, we shall discuss
this and how dysregulated Parkin function may precipitate neuronal demise in various
neurodegenerative disorders.
Keywords: Parkinson’s disease, mitophagy, proteasome, ubiquitin, neurodegeneration, autophagy, protein
misfolding, mitochondria
INTRODUCTION
Parkin is a unique multifunctional ubiquitin ligase whose various roles in the cell, particularly in
neurons, are widely thought to be protective. The pivotal role that Parkin plays in maintaining
neuronal survival is underscored by our current recognition that Parkin dysfunction represents
not only a predominant cause of familial Parkinsonism but also a formal risk factor for the more
common, sporadic form of Parkinson’s disease (PD; Dawson and Dawson, 2014). Moreover,
emerging evidence also implicates a role for Parkin in Alzheimer’s disease (AD), Amyotrophic
Lateral Sclerosis (ALS) and Huntington’s disease (HD; Tsai et al., 2003; Rosen et al., 2010;
Hebron et al., 2014). Further, several studies have documented the ability of Parkin to protect
neurons against a wide variety of insults, including those mediated by neurotoxins and metallic
ions (Kubo et al., 2013). Thus, maintaining an optimal state of Parkin function appears to
be an important determinant of neuronal health in general, although dopaminergic (DA)
neurons whose degeneration is causative of PD seems particularly sensitive to Parkin deficiency.
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Mutations in Parkin were originally identified in Japan
more than a decade ago to be a major genetic contributor
of Autosomal Recessive Juvenile Parkinsonism (ARJP; Kitada
et al., 1998). Following this discovery, several ethnically diverse
individuals with early-onset PD (age <45 years) in other parts
of the world were also found to carry Parkin mutations,
which occur at a frequency of about 10–20 and 50% in
sporadic and familial early-onset cases respectively (Lücking
et al., 2000; Periquet et al., 2003; Mata et al., 2004). At
around the same period, three independent groups demonstrated
that Parkin functions as an E2-dependent ubiquitin ligase
associated with the ubiquitin-proteasome system (UPS; Imai
et al., 2000; Shimura et al., 2000; Zhang et al., 2000), a
major intracellular protein degradationmachinery, which fuelled
intense research on the role of Parkin in neuronal protein
homeostasis. The particular excitement in this topic was in
part also due to the finding that the first PD-linked gene
elucidated before Parkin, i.e., α-synuclein, encodes a presynaptic
protein that tends to misfold and that was subsequently
found to be a major component of Lewy Bodies (LBs), a
histological hallmark of the PD brain (Spillantini et al., 1997).
It seemed intuitive therefore to associate UPS dysfunction
with PD pathogenesis. Further support for this soon came
with the elucidation of another PD-linked gene, i.e., UCH-
L1, which encodes yet another component of the UPS. One
could therefore readily appreciate that it was then a hugely
popular trend to look at the ‘‘proteasome theory of PD’’ (and
subsequently, the related ‘‘autophagy theory of PD’’). Parkin
was soon found to be involved in both UPS- and autophagy-
associated protein quality control (QC; Lim and Zhang, 2013).
However, along the way, several groups (particularly those
working with Drosophila Parkin models) also documented
an intriguing relationship between Parkin and mitochondrial
QC, i.e., mitochondria tends to become abnormal in the
absence of functional Parkin (Greene et al., 2003). This
phenomenon remains largely unexplained and overlooked until
2008, when a seminal discovery by a team led by Richard
Youle demonstrated that Parkin is a key mammalian regulator
of mitochondrial autophagy, or ‘‘mitophagy’’ (Narendra et al.,
2008). Subsequent studies by his group and several others
revealed that Parkin collaborates with another PD-linked gene
product known as PINK1 (encoding a mitochondrial-targeted
serine/threonine kinase) to mediate mitophagy (Geisler et al.,
2010; Matsuda et al., 2010; Narendra et al., 2010a; Vives-
Bauza et al., 2010). Collectively, these reports triggered an
explosion of interest among the global mitochondria and
PD research community in delineating the pathways involved
in Parkin/PINK1-mediated mitophagy, with the excitement
ensuing to this date. Meanwhile, the ‘‘mitochondrial theory of
PD’’ that was popular in the eighties and nineties but had lay
‘‘dormant’’ subsequently is now enjoying its ‘‘renaissance’’ of
support.
Notwithstanding the periodic bias in favor of a particular
disease-associated pathway, it is now evident that Parkin
is an important regulator of protein and mitochondrial
homeostasis that operates against the backdrop of a multitude
of intracellular pathways. Accordingly, the ubiquitin ligase
itself would need to be exquisitely regulated to fulfil its
diverse cellular roles in a timely fashion to maintain optimal
neuronal function. In this review, we shall discuss the
mechanisms underlying Parkin activity regulation and its
involvement in protein/mitochondrial homeostasis and finally,
how dysregulated Parkin function may predispose neurons to
degeneration.
STRUCTURE AND REGULATION OF
PARKIN ACTIVITY
Structurally, the 465 amino acid-containing human Parkin
protein is comprised of a ubiquitin-like (Ubl) domain at
its N-terminus, a RING1-IBR-RING2 (RBR) domain at its
C-terminus and a unique middle segment that links the two
domains. A zinc-chelating RING0 domain that is juxtaposed
(N-terminally) to the RBR domains resides within the linker
segment. Another motif, known as the Repressor Element
of Parkin (REP), sits between the IBR and RING2 domains
(Figure 1). During Parkin-mediated ubiquitination, E2 enzymes
are first recruited to RING1 domain and the charged ubiquitin
they carry are then transferred to a catalytic cysteine (C431) in the
RING2 domain before being finally transferred to the primary
amino group of the substrate via an iso-peptide bond formation.
This is an intriguing catalytic mechanism for a RING-containing
E3 as the process is reminiscent of HECT domain-containing
ubiquitin ligases.We now know that RBR E3 s such as Parkin and
HHARI use such a RING-HECT hybrid mechanism for catalysis
(Wenzel et al., 2011). Interestingly, structural studies of Parkin
revealed that the enzyme exists in a closed, inactivated state under
normal conditions. This auto-inhibited state is achieved through
an intricate folding of the protein whereby RING0 is inserted
between RING1 and RING2 and in so doing occludes the active
site on RING2. At the same time, the closed conformation also
promotes the REP to adopt a structure that lies across the putative
E2-binding site on RING1 thus preventing its recruitment of E2 s
(Riley et al., 2013; Trempe et al., 2013; Wauer and Komander,
2013; Figure 1). Consistent with this, both Helen Walden’s
group and ours have shown experimentally that the N-terminal
region of Parkin represses Parkin-mediated polyubiquitination,
although an important difference between the two studies is
the repressing element involved, i.e., we have proposed the
linker segment (amino acid 152–237 – that contains the RING0
domain) to be the repressing element whereas Walden’s group
showed that it is the Ubl domain (Chaugule et al., 2011; Chew
et al., 2011). Notwithstanding this, for Parkin to become active,
it is obvious that substantial rearrangements of its structure
need to take place to allow the dissociation of RING0 from
RING2 as well as REP from RING1 among other conformational
changes.
Recent studies have revealed that Parkin activity may
be stimulated by a two-step process that involves the
phosphorylation of serine 65 (S65) in its Ubl domain (Matsuda
et al., 2010; Kondapalli et al., 2012; Shiba-Fukushima et al.,
2012) and the phosphorylation of ubiquitin at the same
site (Kane et al., 2014; Koyano et al., 2014). Interestingly,
whereas phosphorylation of Parkin’s Ubl domain promotes
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FIGURE 1 | Structure of regulation of Parkin. Top, Schematic depiction of parkin structure. Bottom, A model of Parkin activity regulation—Under normal
conditions, Parkin exists in an auto-inhibited state where access to its E2-binding RING1 site is occluded by its Ubl and repressor element of parkin (REP) domains
and access to its RING2’s active site is blocked by the RING0 domain. Upon the phosphorylation Parkin’s Ubl domain by PINK1 at Serine 65 (S65) and the
concomitant engagement of RING1 with phosphorylated ubiquitin, the Ubl is displaced away from RING1, which led to the structural rearrangement of the various
domains of Parkin. The enzyme consequently becomes fully activated.
its dissociation from RING1, the phosphorylation of ubiquitin
(also at S65) enhances its association with RING1. Thus,
despite the fact that Ubl and ubiquitin share marked sequence
similarities, their respective interaction with RING1 of Parkin
is oppositely regulated by phosphorylation. Precisely how these
phosphorylation events could alter the multiple intra-molecular
interactions that define the auto-inhibited enzyme to bring
about its activation was unclear until very recently. A number
of new structural studies on Parkin have now clarified the
mechanism of Parkin activation (Kumar et al., 2015; Sauvé et al.,
2015; Wauer et al., 2015). In essence, the concerted finding
is that the dissociation of Ubl from RING1 (following S65
phosphorylation) exposes a histidine residue (H302) on RING1
that binds to phosphorylated ubiquitin, which leads to the
displacement the Ubl domain from its original conformation,
loss of structure near the RING1/IBR interface and the overall
relieve of Parkin’s auto-inhibited state (Figure 1). RING1
now becomes available for the engagement with E2∼ubiquitin
conjugate to trigger downstream substrate ubiquitination.
Although these structural studies have certainly contributed
to a clearer picture of Parkin activation, how the activated
enzyme returns to its basal auto-inhibited state remains elusive.
Presumably, this will involve the dephosphorylation of S65-
phosphorylated Ubl domain and ubiquitin by an unknown
phosphatase(s). Moreover, because the above model of Parkin
activation is related to its function in mitophagy, it is also unclear
whether the same activation mechanism is utilized to promote
Parkin-mediated ubiquitination in non-mitophagy events.
Parkin’s role in the cell is certainly not restricted to protein
turnover during mitophagy. As a matter of fact, the majority of
reports before 2008 described its role in protein QC that is not
directly related to mitophagy.
PARKIN AND PROTEIN HOMEOSTASIS
As mentioned earlier, Parkin functions as an E3 ligase associated
with the UPS, a major proteolytic machinery that normally
identifies and degrades unwanted intracellular proteins. In this
system, proteins that are destined for proteasome-mediated
degradation are added a chain of ubiquitin via a reaction cascade
that involves the ubiquitin-activating (E1), -conjugating (E2) and
-ligating (E3) enzymes. Through the sequential and repetitive
actions of these enzymes, successive isopeptide linkages are
formed between the C-terminal glycine carboxyl group (G76)
of the ubiquitin moiety being added and the α-amino group
of a free lysine (most commonly K48) on the ubiquitin that
is attached to the protein. The (G76-K48) polyubiquitinated
substrate is then recognized by the 26S proteasome as a target
for degradation. It is important to highlight that the ubiquitin
sequence contains seven lysine residues (at positions 6, 11,
27, 29, 33, 48 and 63) and that polyubiquitin chain assembly
can occur at any of these lysine residues (Peng et al., 2003).
In addition, proteins can also be monoubiquitinated. Notably,
both K63-linked polyubiquitination and monoubiquitination of
proteins are not typically associated with proteasome-mediated
ubiquitination.
Along with the original discovery by three independent
groups who demonstrated that Parkin functions as a ubiquitin
ligase, they also found that disease-associated Parkin mutations
compromise its role as an E3 enzyme (Imai et al., 2000;
Shimura et al., 2000; Zhang et al., 2000). A logical and popular
hypothesis that ensued is that loss of Parkin function would lead
to the toxic accumulation of one or several of its substrates,
thereby leading to neurodegeneration. This had fuelled intense
effort by many laboratories around the world to identify the
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culprit substrate(s) involved. To date, no less than 25 substrates
(or putative substrates) of Parkin have been reported (Table 1).
However, none of the Parkin substrates identified thus far is
exclusively expressed in DA neurons, which raises the question
on why DA neurons in familial Parkinsonism cases linked to
Parkin mutations are rather selectively vulnerable to deficient
Parkin function. Of course, one could argue that neither is
Parkin expression confined to DA neurons and therefore it is
perhaps not surprising to note the broad distribution of its
substrates as well. Importantly, few from the laundry list of
Parkin substrates fulfil an important criterion expected of an
‘‘authentic’’ Parkin substrate, i.e., accumulation in the brains of
ARJP patients and Parkin-deficient models. Although the pace of
substrate identification has slowed down considerably in recent
years, new Parkin substrates continue to emerge periodically,
especially those related to the mitochondria. Among the recently
isolated Parkin substrates is the zinc finger-containing protein
called PARIS (ZNF746; Shin et al., 2011), a major transcriptional
repressor of PGC-1α expression, which in turn regulates the
transcription of many genes involved in cellular metabolism.
Importantly, unlike most previously identified Parkin substrates,
PARIS was shown to accumulate in post-mortem brain tissues
derived from ARJP and sporadic PD patients, as well as
in the ventral midbrain region of mice that is conditionally
ablated of Parkin expression (Shin et al., 2011). Based on these
findings, the authors proposed that PARIS is an ‘‘authentic’’
Parkin substrate. More recently, and some may think curiously,
Parkin was found to interact with the anaphase promoting
complex/cyclosome (APC/C) coactivators Cdc20 and Cdh1
to mediate the degradation of several key mitotic regulators
independent of APC/C. Accordingly, its deficiency results in
the elevated expression of these substrates leading to mitotic
defects, genomic instability and tumorigenesis (Lee et al., 2015).
Corroborating with these findings, we and others have previously
similarly shown that Parkin dysfunction underlies several types
of cancers (Cesari et al., 2003; Tay et al., 2010; Yeo et al., 2012).
Although not directly related to the current review topic, the
several recent reports collectively pointing towards a role for
Parkin as a tumor suppressor suggest the interesting possibility
that Parkin-related neurodegeneration may arise from aberrant
cell cycle re-entry in post-mitotic neurons.
Notwithstanding that only a handful of substrates reported
to date could fulfil the restricted criterion of a Parkin substrate
(as mentioned above), what constitutes an ‘‘authentic’’ substrate
for Parkin is really debatable. Although protein ubiquitination
is classically associated with proteasome-mediated degradation,
the existence of non-classic ubiquitin modifications such
as K63-linked polyubiquitination would caution against the
fixation on the traditional view that substrates of a ubiquitin
ligase must exhibit an accelerated, proteasome-dependent
TABLE 1 | A selection of reported Parkin substrates.
Substrates Ub Type Elevated Reference
KO mice ARJP brain PD brain
Ataxin-2 – Yes – – Huynh et al. (2007)
Ataxin3 polyQ79 – – – – Tsai et al. (2003)
Bcl-2 Mono – – – Chen et al. (2010)
CDCrel-1 – Yes/No Yes/No – Ko et al. (2005)
CDCrel-2a – – Yes – Choi et al. (2003)
Cyclin E – No Yes/No Yes Staropoli et al. (2003) and Ko et al. (2005)
DJ-1 L166P K63 – – – Olzmann et al. (2007)
Dopamine Transporter – – – – Jiang et al. (2004)
Drp1 K48 – – – Wang et al. (2011a)
ps15 Mono – – – Fallon et al. (2006)
FBP1 – Yes Yes Yes Ko et al. (2006)
Fbw7β K48 Yes Yes – Ekholm-Reed et al. (2013)
Hsp70 Multiple No No Yes Moore et al. (2008)
Mono
LIM Kinase – – – – Lim et al. (2007)
Mitofusin – – – – Poole et al. (2010) and Ziviani et al. (2010)
O-glycosylated α-synuclein – – Yes – Shimura et al. (2001)
P38/AIMP2 Multiple Yes Yes Yes Corti et al. (2003), Ko et al. (2005), Periquet et al. (2005) and Hampe et al. (2006)
Mono
Pael-R – No Yes/No – Ko et al. (2005)
PARIS (ZNF746) K48 Yes Yes Yes Shin et al. (2011)
PDCP2–1 – – Yes Yes Fukae et al. (2009)
Phospholipase Cγ1 – Yes – – Dehvari et al. (2009)
PICK1 Mono No – – Joch et al. (2007)
RanB2 – – – – Um et al. (2006)
Synaptotagmin XI – Yes/No – – Periquet et al. (2005)
Synphilin-1 K63 No No – Chung et al. (2001), Ko et al. (2005) and Lim et al. (2005)
VDAC1 K27, Mono Yes – – Periquet et al. (2005), Geisler et al. (2010) and Narendra et al. (2010b)
α/β tubulin – Yes/No No – Ren et al. (2003) and Ko et al. (2005)
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turnover in the presence of the enzyme. This is particularly
relevant to Parkin, which we and others have demonstrated to
be a multifunctional enzyme capable of mediating alternative
ubiquitin topologies such as monoubiquitination and K63-
linked polyubiquitination—modifications that are typically
uncoupled from the proteasome and often considered as
‘‘non-proteolytic’’ (Doss-Pepe et al., 2005; Lim et al., 2005;
Hampe et al., 2006; Matsuda et al., 2006). Our results would
suggest that the catalytic function of Parkin is not limited to
targeting substrate for degradation by the proteasome. Thus,
the lack of accumulation of an identified Parkin substrate
in the brains of ARJP patients and Parkin-deficient models
does not necessarily mean that it is less than an ‘‘authentic’’
substrate. For example, we have previously reported that Parkin-
mediated polyubiquitination of synphilin-1 (an interactor of
α-synuclein) normally occurs via K63-linked chains, which does
not appear to affect its steady-state turnover (Lim et al., 2005).
Not surprisingly, the level of synphilin-1 is neither appreciably
altered in ARJP brains nor in brain tissues derived from Parkin
null mice (Ko et al., 2005). A corollary to this is that proteasome-
independent pathways may also be relevant to Parkin-related
neurodegeneration. By virtue of its apparent dissociation from
the proteasome, we have originally proposed that Parkin-
mediated K63-linked ubiquitination may be involved in cargo
diversion during proteasomal stress and accordingly, in the
biogenesis of inclusion bodies associated with neurodegenerative
diseases (Lim et al., 2006). Our proposal is consistent with the
concept of ‘‘aggresomes’’, which are juxtanuclear inclusion
bodies formed in the presence of proteasomal stress and that
have been suggested to act as staging grounds for the disposal
of protein aggregates via the autophagic route (Kopito, 2000).
Supporting our hypothesis, we found that Parkin-mediated K63
polyubiquitination of synphilin-1 promotes its aggregation into
aggresome-like inclusion bodies (Lim et al., 2005). Corroborating
our findings, Olzmann et al demonstrated that Parkin-mediated
K63 polyubiquitination of misfolded DJ-1 couples the protein
to the dynein motor complex via the histone deacetylase 6
(HDAC6) adaptor, thereby promoting its sequestration into
aggresomes (Olzmann et al., 2007). Importantly, we further
identified K63-linked polyubiquitin as a cargo selection signal
for macroautophagy-mediated clearance of aggresomes (Tan
et al., 2008a,b). Notably, Wang et al. (2012) demonstrated that
the formation of aggresomes mediated by mutant superoxide
dismutase 1 (SOD1) is dependent on ataxin 3-catalyzed editing
of K63-linked polyubiquitin chain on SOD1 (presumably to
a correct length) which supports our findings. In a similar
development, Hao et al. (2013) demonstrated that the disposal
of aggresomes requires the proteasomal deubiquitinating
enzyme Poh1, which releases free (K63-linked) ubiquitin chains
from aggresomes that activates HDAC6-dependent autophagy
clearance of the cargo. In Poh1-deficient cells, aggresome
clearance is blocked but may be rescued by the introduction of
free K63-linked ubiquitin chains (via microinjection). Finally,
by means of ubiquitin linkage-specific antibodies, we recently
showed that proteasome inhibition indeed promotes K63-linked
ubiquitination of proteins especially in Parkin-expressing
cells (Lim et al., 2013). Importantly, we further demonstrated
that the recruitment of Ubc13 (an E2 that mediates K63-
linked polyubiquitin chain formation exclusively) by Parkin is
selectively enhanced under conditions of proteasomal stress,
which favors aggresome formation and thereby the clearance
of Parkin substrates via autophagy (Lim et al., 2013). Thus,
by being capable of mediating both proteasome-associated
K48-polyubiquitination and macroautophagy-associated K63-
linked polyubiquitination, Parkin may potentially act as an
important triage between the two major cellular degradation
systems (Figure 2). This multi-functionality of Parkin may in
part help explain its apparent broad neuroprotective properties,
as the flexibility of ubiquitin linkage usage presumably would




One of the first hints that Parkin may play a role in
mitochondrial homeostasis aside from its role as a regulator
of protein turnover came from a study by Greene et al.
(2003) in fruit flies. The authors analyzed adult Drosophila
parkin null mutant and observed that the most prominent
pathology is not in the brain but in the flight musculature of
these mutant flies, which is plagued by muscle degeneration
and pronounced mitochondrial lesions. Interestingly, pink1
null flies were subsequently found to phenocopy their parkin-
deficient counterparts and importantly, parkin over-expression
in pink1−/− flies were shown to be capable of rescuing all the
mutant phenotypes tested, although the reverse, does not happen
(Clark et al., 2006; Park et al., 2006), suggesting that Parkin
acts in the same pathway but downstream of PINK1. Several
follow-up studies in flies and other model systems that attempted
to explain the mitochondrial phenotype focused initially on
the role of Parkin/PINK1 pathway in mitochondrial dynamics,
although whether the pathway promotes mitochondrial fission
or fusion remains controversial to this date (for a recent review,
see Burbulla et al., 2010). Besides potentially participating in
mitochondrial dynamics, Parkin, as we have noted earlier, is also
involved in mitochondrial biogenesis by virtue of its ability to
regulate PGC-1α indirectly through its ability to down-regulate
PARIS (Shin et al., 2011), a major transcriptional repressor of
PGC-1α (Scarpulla, 2008). The repression of PGC-1α (a key
regulator of mitochondrial biogenesis) by PARIS is expected
to result in reduced mitochondrial mass, which if unregulated
could compromise the ability of the cell to adapt to energy
crises.
In recent years, much attention on the relationship between
Parkin function and mitochondrial homeostasis has been shifted
to its role in mitophagy. As several excellent reviews on
Parkin/PINK1-mediated mitophagy have been written on this
topic (for example, see Durcan and Fon, 2015; Pickrell and
Youle, 2015), we will only briefly describe the model here, as
depicted in Figure 3. Until recently, the model describes a
linear sequence of events occurring in response to mitochondrial
depolarization that culminates in their removal. According to
the proposed model (Youle and Narendra, 2011), a key initial
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FIGURE 2 | Proposed model of Parkin’s role as a triage between proteasome and autophagy degradation. Under normal cellular conditions, proteins
destined for degradation by the proteasome are tagged with a chain of K48-linked ubiquitin. In times of proteolytic stress, the cell switches to K63-linked
ubiquitination to divert the protein load originally targeted for proteasomal degradation away from the otherwise overloaded machinery. Parkin facilitates this switch
by increasing its affinity for Ubc13 in the presence of proteasome dysfunction.
event that occurs upon mitochondrial depolarization is the
selective accumulation of PINK1 on the outer membrane of
the damaged organelle. This accumulation allows PINK1 to
recruit Parkin (Okatsu et al., 2012), whose latent ubiquitin ligase
activity becomes unmasked along the way in part due to its
phosphorylation by PINK1 (Matsuda et al., 2010; Kondapalli
et al., 2012). PINK1 also phosphorylates ubiquitin, which binds
and activates Parkin (Kane et al., 2014; Koyano et al., 2014). We
now know from several recent structural studies discussed above
how the dual phosphorylation events mediated by PINK1 lead
to the release of Parkin’s auto-inhibited state. Activated Parkin
then promotes the ubiquitination and subsequent degradation
of many outer mitochondrial membrane (OMM) proteins
(Chan et al., 2011; Yoshii et al., 2011). During the process,
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FIGURE 3 | An updated model of PINK1/Parkin-mediated mitophagy. (1) In healthy mitochondria, there is no accumulation of PINK1 on the outer
mitochondrial membrane (OMM) as the protein is rapidly imported, processed and degraded. (2) Upon mitochondrial depolarization, full length PINK1 accumulates
on the OMM leading to the phosphorylation of ubiquitin on the surface of the mitochondria. This results in the recruitment of the autophagy receptors optineurin
(OPTN) and NDP52 and the consequent activation of the mitophagy process, albeit at low level. (3) Parkin is also recruited to the OMM, whose latent activity
becomes unmasked due to its interaction with phosphorylated ubiquitin and its phosphorylation by PINK1. (4) Activated Parkin promotes the polyubiqutination of
mitochondrial substrates that in turn provides more ubiquitin substrates for PINK1 to phosphorylate. This amplifies the signal for the recruitment of autophagy
receptors and results in robust mitophagy.
Parkin-decorated mitochondria progressively cluster towards
the peri-nucleus region to form ‘‘mito-aggresomes’’ (Lee et al.,
2010), which by virtue of their association with lysosomal
components are removed with time in an autophagy-dependent
manner. Although this linear model explains the selectivity of the
mitophagy process rather elegantly, recent discoveries revealed
that a more complicated network of molecular interactions is
involved in the disposal of unwanted mitochondria (Heo et al.,
2015; Lazarou et al., 2015). In essence, these studies demonstrated
that mitochondrial-localized PINK1 is able to recruit the
autophagy receptors optineurin (OPTN) and NDP52 in the
absence of Parkin and that this phenomenon alone is sufficient
to trigger mitophagy, albeit at a low level. The recruitment
of OPTN and NDP52 is dependent on PINK1-mediated
phosphorylation of ubiquitin, which serves as autophagy signal
on the mitochondria. Parkin promotes the process by amplifying
the phospho-ubiquitin level generated by PINK1 that otherwise
occurs at a low level due to the limited basal ubiquitin
availability on mitochondria. In so doing, Parkin mediates
a positive feed-forward cycle that generates more ubiquitin
substrates on the OMM for PINK1 to phosphorylate that in
turn facilitates the recruitment of autophagy receptors thereby
enhancing the mitophagy process. Adding to this complexity is
the recent elucidation by several groups that deubiquitinating
enzymes (DUBs) such as USP8, USP15, USP30 and USP35 can
counteract Parkin-mediated mitochondrial ubiquitination and
consequently mitophagy, although they generally do not affect
the recruitment of Parkin to damaged mitochondria (Bingol
et al., 2014; Cornelissen et al., 2014; Durcan et al., 2014; Wang
et al., 2015).
Notwithstanding the elegance of the proposed mitophagy
model, whether the process occurs in post-mitotic neurons
that are obligatorily dependent on mitochondrial respiration is
contentious. Intuitively, one would logically accept the need for
neurons to embark on mitophagy for QC reasons but perhaps
in a more limited fashion. An example of this scenario is when
damage of mitochondria occurs in at the distal ends of neurons.
In this case, the motility of the restricted population of damaged
mitochondria has been shown to be arrested. This occurs via the
degradation of the mitochondrial motor adaptor protein Miro
in a pathway also mediated by PINK1 and Parkin, the effect of
which leading to arrested motility suggests that PINK1/Parkin
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pathway may quarantine damaged mitochondria prior to their
clearance (Wang et al., 2011b; Ashrafi et al., 2014). Interestingly,
a recent study provided evidence that Parkin-mediated neuronal
mitophagy does occur in vivo. The investigators found that the
brains of Parkin mutant flies exhibit a significantly decreased
rate of mitochondrial protein turnover, which is similar to
that produced by general autophagy blockade induced by the
genetic ablation of atg7, suggesting that Parkin indeed promotes
mitochondrial turnover through autophagy and that the process
is physiologically relevant, albeit in the fly (Vincow et al., 2013).
Apart from mitophagy, PINK1/Parkin-dependent
mitochondrial QC also occurs via an alternative pathway
involving mitochondria-derived vesicles (MDVs). During
various forms of mitochondrial stress, MDVs are formed from
the budding of membranes from the mitochondria, which
mediate the transport of damaged mitochondrial proteins
and lipids to other intracellular organelles. The nature of
mitochondrial stress is an important determinant of the
constituents of its cargo, which in turn determine the fate of
MDVs. For example, MDVs containing MAPL, an OMM-
anchored protein ligase, exclude other OMM markers such
as TOM20 and are selectively targeted to a subpopulation of
peroxisomes (Neuspiel et al., 2008). Other MDVs that are not
destined to the peroxisome fused instead with late endosomes
(or multivesicular bodies), which ultimately target them for
lysosomal degradation (Soubannier et al., 2012a). Importantly,
the generation of late endosome-targeted mitochondria is
dependent on PINK1 and Parkin and occurs under moderate
mitochondrial stress as opposed to acute mitochondrial
toxin treatment that leads to mitophagy. Furthermore, this
phenomenon that is independent of ATG5 and LC3 does
not require mitochondrial depolarization, suggesting that
this pathway complements mitophagy and contributes to
mitochondrial QC (Soubannier et al., 2012a,b; Sugiura et al.,
2014). In another scenario, we have recently found that
chronic, low dose CCCP treatment promotes Parkin-mediated
mitochondrial fusion instead of mitophagy (Norris et al.,
2015). In principle, active fusion could protect mitochondrial
integrity by complementing damaged mitochondria with their
healthy counterparts or by limiting the production of ROS. This
adaptive mitochondrial fusion strategy that we have found in
the presence of low but chronic mitochondrial stress is likely
more physiologically relevant to the disease than high dose
mitochondrial toxins commonly used to induce acute neuronal
dysfunction. Importantly, we further showed that Parkin,
PINK1 and α-synuclein form a regulatory circuit to regulate
mitochondrial stress response, thus functionally connecting
three key PD-linked genes to the pathogenesis of PD. To clarify,
our result does not exclude the need for neuronal mitophagy,
especially when mitochondria become chronically damage with
time. It does however emphasize the need to pay close attention
to the conditions used in mitophagy-related experiments and
that mitochondrial QC involves not just its turnover. Whatever
it is, it is evident from various studies above that Parkin appears
to be involved in the entire spectrum of mitochondrial dynamics,
i.e., from biogenesis, fusion/fission, intracellular movements to
its exit from the cell.
PARKIN DYSREGULATION AND PD
PD is a prevalent neurodegenerative disease that is characterized
clinically by a constellation of motoric deficits arising principally
from the loss of midbrain DA neurons in the substantia nigra
pars compacta (SNpc) that is often accompanied by the presence
of LBs in surviving neurons in the SN and other affected brain
areas (Braak et al., 2003). Given the pivotal role that Parkin plays
in regulating protein and mitochondrial homeostasis, and that
DA neurons are usually in a heighten state of stress relative
to other neuronal populations, it is perhaps not surprising to
note that Parkin dysregulation can result in PD-associated DA
neurodegeneration. Moreover, several studies also implicated a
more direct role for Parkin in neuroprotective signaling. For
example, Parkin-mediated ubiquitination was demonstrated to
be important for the activation of major cellular pro-survival
pathways such as the NF-κB pathway (Henn et al., 2007), or the
suppression of stress-related mitogen-activated protein kinase
signaling (e.g., JNK and p38; probably indirectly through its
ability to counteract oxidative stress; Cha et al., 2005; Ren et al.,
2009). Accordingly, loss of Parkin function would be dire for
neuronal survival.
Using phosphorylated ubiquitin as a surrogate marker for
mitophagy (or at least the activation of which), Fiesel et al.
(2015) recently presented evidence that mitophagy is defective
in the brains of PD patients. By means of phospho-specific
ubiquitin immunostaining that only recognizes the presence
of S65-phosphorylated ubiquitin (pS65-Ub), the authors found
that the level of pS65-Ub (that is barely detectable under basal
condition) is elevated in cells in response to mitochondrial
stress (Fiesel et al., 2015). Importantly, they further found that
pS65-Ub accumulates in human brain during aging and in
post-mortem PD brain samples. Whether a (hitherto unknown)
phosphatase returning pS65-Ub to its basal state is deficient in
aged or sporadic PD brains that had resulted in the observed
increase in pS65-Ub level is presently unclear. Nonetheless,
mitophagy defects seem to be associated with PD pathogenesis.
Obviously, Parkin dysfunction can also trigger impairments
in neuronal protein homeostasis. Again, using PARIS as an
example to illustrate this, its overexpression (via stereotactic
injection of viral vector encoding PARIS) in the SN of mice
was shown to result in a selective loss of DA neurons. This
phenotype can be rescued by either Parkin or PGC-1α co-
expression, suggesting that PARIS upregulation may underlie
neurodegeneration due to Parkin activation (Shin et al., 2011).
Along the same vein, Ekholm-Reed et al. (2013) recently found
that the SCF substrate adapter Fbw7β is a target of Parkin during
acute oxidative stress and that it accumulates in Parkin-deficient
neurons. A consequence of Fbw7β accumulation is that the
level of Mcl-1, an anti-apoptotic protein substrate of SCFFbw7β-
mediated degradation, is depleted. Loss of Parkin may thus lead
to the death of DA neurons through unregulated SCFFbw7β-
mediated ubiquitination-dependent proteolysis of Mcl-1, which
again illustrates the need to for Parkin to maintain tight
homeostatic control over its substrates for optimal neuronal
function. However, a more recent study demonstrated that Mcl-
1 is also targeted by Parkin for degradation (Carroll et al., 2014)
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so the verdict regarding the relationship between Parkin and the
anti-apoptotic protein Mcl-1 is currently open.
Given the neuroprotective function of Parkin, understanding
how Parkin dysregulation occurs in the PD brain is an important
endeavor to pursue that has obvious therapeutic implications.
From the studies conducted to date, we now appreciate that
Parkin dysfunction could happen under a variety of conditions.
To begin with, several disease-associated mutations of Parkin
directly result in the loss of its enzymatic activity. These include
exon deletions that lead to the considerable truncation of the
protein and missense mutations that reside on its catalytic
RING2 domain. In cases where the missense mutation occurs
outside of Parkin’s RING2 domain (i.e., not affecting its catalytic
competency), its solubility is often altered that consequently
promotes its aggregation and thereby immobilization into
inclusion bodies (Ardley et al., 2003; Cookson et al., 2003; Gu
et al., 2003; Muqit et al., 2004; Sriram et al., 2005; Wang et al.,
2005b; Hampe et al., 2006). Interestingly, among the aggregation-
producing Parkin mutations is the R275W substitution, which
frequently occurs in the heterozygous state. Although the implied
pathogenicity of single heterozygous Parkinmutation contradicts
the widely accepted notion that Parkin mutations transmit in
a classical autosomal recessive manner, one could envisage that
Parkin haploinsufficiency arising from such mutations could
increase the risk of heterozygous Parkin carriers for PD especially
in view of the importance of optimal Parkin expression to
neuroprotection. Indeed, several lines of evidence support the
proposal that a single allelic hit on Parkin might be sufficient
to cause disease (Hilker et al., 2001; Walter et al., 2004;
Buhmann et al., 2005). Alternatively, some mutations of Parkin
may compromise its function by destabilizing the protein and
accelerating its degradation via the proteasome (Schlehe et al.,
2008).
That Parkin mutations transmit in a recessive manner would
suggest that the loss of Parkin function predisposes DA neurons
to degeneration. An important corollary to this is that any post-
translational event that promotes the loss of Parkin function
could potentially mimic the effects brought about by overt
mutations and be just as detrimental. Further, in view of the
suggested contribution of Parkin haploinsufficiency to disease
risk, it is reasonable to assume that the down-regulation of
normal Parkin function mediated by such events need not
result in the total abolition of its enzymatic activity to elicit
a pathogenic effect. Notably, we and others have found that
a wide variety of PD-linked stressors, including those that
produce oxidative and nitrosative stress, induce Parkin solubility
alterations and thereby its aggregation in a manner that is
analogous to that brought about by several of its missense
mutations (Winklhofer et al., 2003; LaVoie et al., 2005; Wang
et al., 2005a). Remarkably, dopamine also modifies Parkin in a
similar fashion (LaVoie et al., 2005; Wang et al., 2005a). Further,
Parkin appears to be uniquely susceptible to dopamine-induced
modifications compared to several other related E3 members
such as HHARI, Cbl and CHIP (LaVoie et al., 2005, 2007; Wong
et al., 2007). Like haploinsufficiency, the biochemical depletion
of soluble Parkin levels is expected to increase the vulnerability
of susceptible neurons to degeneration. Interestingly, normal
Parkin in the brain also becomes progressively more detergent-
insoluble with aging (Pawlyk et al., 2003), which may provide
an explanation to why age represents a risk factor for PD.
Besides stress-induced modifications, Parkin phosphorylation
is another post-translational modification that could alter its
activity. Unlike PINK1-mediated phosphorylation of Parkin that
activates the enzymes, previous studies have demonstrated that
Parkin phosphorylation by casein kinase 1 (CK1; at Ser-101,
-127, -131, -136, -296, -378) or cyclin-dependent kinase 5 (Cdk5;
at Ser-131) down-regulates its activity, and that compound
phosphorylation of Parkin by both kinases further leads to
its aggregation (Yamamoto et al., 2005; Avraham et al., 2007;
Rubio de la Torre et al., 2009), Consistent with this, Parkin
phosphorylation was found to be elevated in distinct regions
of sporadic PD brains and correlates with increased levels
of p25, the activator of CDK5 (Rubio de la Torre et al.,
2009). Notwithstanding this, how the various phosphoserines on
Parkin modulate its activity remains unclear, especially when the
majority of these residues lie outside the regulatory RING0 box of
the linker segment of Parkin. Similar to serine phosphorylation,
tyrosine phosphorylation of Parkin at residue 143 (Y143) by the
src family kinase member, c-Abl, similarly inactivates its enzyme
activity and compromises its protective function both in vitro and
in vivo. This form of modified Parkin is also found elevated in
human post-mortem PD brains (Ko et al., 2010). Besides post-
translational modifications, a number of Parkin interactors have
also been demonstrated to be capable of inactivating its E3 ligase
activity. These include the bcl-2-associated athanogene 5 (BAG5)
and 14–3–3η whose association with Parkin reduces its activity
and Nrdp1, a RING-finger containing ubiquitin ligase promotes
Parkin degradation and depletes the availability of Parkin to the
cell (Kalia et al., 2004; Zhong et al., 2005; Sato et al., 2006). These
events if unregulated would obviously be detrimental to Parkin’s
protective function.
Taken together, it is apparent that loss of Parkin function
is not limited to those induced by disease-causing mutations,
but also includes several biochemical and protein-protein
modifications that can either alter the catalytic function
of the E3 ligase directly, or indirectly through promoting
its aggregation or degradation. Collectively, these mutation-
independentmodifications that inactivate Parkin activity provide
a mechanism for Parkin dysfunction that is relevant to
the pathogenesis of sporadic PD. At the same time, they
also suggest therapeutic directions in managing the disease.
Interesting, whereas S-nitrosylation of Parkin leads to its
inactivation, sulfhydration of Parkin has recently been shown
to enhance its activity (Vandiver et al., 2013). Moreover,
the levels of sulfhydrated Parkin is markedly depleted in
PD brains while nitrosylation increased in tandem, suggesting
that hydrogen sulfide donors may counteract S-nitrosylation-
mediated inactivation of the enzyme and may accordingly be
therapeutic. Similarly, the c-Abl inhibitor, nilotinib, is also
protective against DA neuronal loss in a toxin-induced model of
PD, although curiously the level of phospho-Y143 Parkin appears
to be unchanged (Karuppagounder et al., 2014). These recent
studies suitably illustrate the importance of mechanistic insights
in guiding therapeutics development.
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PARKIN DYSREGULATION AND OTHER
NEURODEGENERATIVE DISEASES
Besides PD, accumulating evidence suggests that Parkin
dysfunction may also contribute to the pathogenesis of
other neurodegenerative diseases including AD and ALS.
Pathologically, the AD brain is characterized by the presence
of extracellular amyloid aggregates and intra-neuronal
hyperphosphorylated tau aggregates known as neurofibrillary
tangles (NFTs). Among the first hints suggesting a relationship
between Parkin and AD is the finding by Nemes et al. (2004) that
Parkin is a major component cross-linked by gamma-glutamyl-
epsilon-lysine bonds in AD-associated NFT. More recently,
Corsetti et al. (2015) showed that an N-terminal truncated
tau species found in AD individuals can induce deregulated
mitophagy by aberrant recruitment of Parkin that result in
excessive mitochondrial turnover, synaptic deterioration and
neuronal death, thus providing a Parkin-related mechanism in
the pathogenesis of AD. Notably, a number of earlier studies
have already documented abnormal tau hyperphosphorylation
in patients with Parkin mutations (van de Warrenburg et al.,
2001; Sánchez et al., 2002), suggesting that Parkin deficiency may
precipitate tau pathology. Consistent with this, the accumulation
of tau was observed during ageing in Parkin null mice
(Rodríguez-Navarro et al., 2007). Interestingly, overexpression
of mutant tau in mice against Parkin null background promotes
cerebral and systemic amyloidosis (Rodríguez-Navarro et al.,
2008) that is accompanied by impairments in memory and
exploratory behaviors (Navarro et al., 2008), suggesting that
Parkin may also affect amyloidogenesis. Indeed, Rosen et al.
(2006) reported that Parkin could lower the level of amyloid
burden and protect against its toxicity (albeit in muscle cells).
In a series of follow up studies, the same group and others
demonstrated the ability of Parkin to facilitate the clearance of
the pathogeneic amyloid β42 by reversing its negative effects
on the proteasome and also by enhancing beclin-dependent
autophagy (Burns et al., 2009; Rosen et al., 2010; Khandelwal
et al., 2011). Not surprisingly, Parkin overexpression in an
AD mouse model (that is based on altered amyloid precursor
protein processing, i.e., APPswe/PSEN1∆E9 mutant) was found
to reduce β-amyloid load and improve hippocampal long
term potentiation (Hong et al., 2014). Similar outcomes were
also observed when AD animals were treated with nilotinib,
which increases parkin solubility and its interaction with Beclin
one leading to enhanced amyloid clearance and cognitive
performance (Lonskaya et al., 2013).
In a parallel development, several groups working on
FUS/TLS and TDP-43 related ALS found an association
between these ALS-mutants and Parkin. In an elegant functional
genomics study, Yeo’s group found that among the 45 RNA
species that were reduced following depletion of TDP-43 or
FUS/TLS, one of these encodes Parkin (Lagier-Tourenne et al.,
2012). Consistent with this, mice carrying a knock-in copy
of mutant TDP-43 exhibit reduced level of Parkin expression
(Stribl et al., 2014). Thus, Parkin deficiency may also be
interwoven with the pathogenic events in ALS. Indeed, Hebron
et al. (2014) recently demonstrated the ability of Parkin to
reverse TDP-43-mediated cell death. Apparently, mitochondrial
dysfunction may be an underlying denominator responsible for
neuronal death in ALS as well. Notably, altered mitochondrial
QC was observed in the TDP-43 knock in mutant mice (Stribl
et al., 2014). Moreover, mutations in the autophagy/mitophagy
receptor OPTN are associated with ALS (Maruyama et al.,
2010) and mutant OPTN are apparently incapable of facilitating
Parkin/PINK-mediated mitophagy (Wong and Holzbaur, 2014).
Finally, despite the anatomical and functional relatedness of
HD and PD (i.e., both affect the basal ganglia circuitry and
result in movement disorders), only a handful of reports
suggest that Parkin deficiency may be a contributor to striatal
neurodegeneration in HD. In an earlier study, Parkin was
found to protect against the toxicity induced by expanded
polyglutamine proteins (Tsai et al., 2003). Subsequent to
this, another group found that partial suppression of Parkin
aggravates the phenotype in the huntingtin R6/1 mutant
mice, albeit only slightly (Rubio et al., 2009). More recently,
Parkin/PINK-mediated mitophagy was shown to promote
neuroprotection in fly and mouse models of HD (Khalil et al.,
2015).
In sum, it is evident from the above discussion that Parkin
deficiency is relevant not just to PD but may also be relevant
to several other major neurodegenerative diseases. Obviously,
this begs the question on why mutations in Parkin are uniquely
causative of PD. Although we remain unclear about this, one
possible explanation is that human DA neurons are selectively
vulnerable to the loss of Parkin function perhaps by virtue of their
heighten stress, i.e., Parkin deficiency in this case is the principal
driver of disease pathogenesis. In AD and ALS, the depletion
of Parkin occurs against the backdrop of other pathogenic
factors; the combination of which is likely to aggravate neuronal
loss, i.e., Parkin dysfunction is the co-driver. Arguably, some
may consider Parkin’s role in these diseases as a passenger,
i.e., a consequence of AD or ALS-related pathogenic factors
going awry, although several reports demonstrated that Parkin
overexpression is beneficial in these cases. Whether Parkin is
acting as a driver, co-driver or passenger, we probably could
all accept that its optimal expression is important for neuronal
homeostasis.
CONCLUDING REMARKS
It has been 15 years or so since the function of Parkin was
originally elucidated. Certainly, we now know much more about
the various aspects of the E3 than we did before. Yet, it remains
rather amazing at the same time to note that a single ubiquitin
ligase could possess such multi-functionality that enables it to
perform diverse types of ubiquitination (including mono, K48-
and K63-linked ubiquitin modifications) to support a plethora
of cellular processes, as well as lend itself as a broad spectrum
neuroprotectant. As articulated above, emerging evidence also
suggests its relevance to several major neurodegenerative diseases
besides PD, and interestingly, to cancer development as well.
Thus, Parkin appears to be one of a kind. Accordingly, its
activity regulation must be exquisitely controlled in different cell
types under different conditions for optimal cellular function.
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On a related note, given the amazing properties of this
RING-containing E3, we thought that it would be appropriate
to end this article by suggesting that Parkin be (affectionately)
nicknamed as the ‘‘Lord of the RING’’. Obviously, we are bias
here and concede that some readers may consider Parkin as just a
‘‘RING-bearer’’. Be it the lord or a RING-bearer, we cannot deny
the fact that Parkin does have some very enchanting properties.
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